Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PTGX 
Protagonist Therapeutics Inc (PTGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: PTGX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $69.73
1 Year Target Price $69.73
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 64.72% | Avg. Invested days 52 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.67B USD | Price to earnings Ratio 80.89 | 1Y Target Price 69.73 |
Price to earnings Ratio 80.89 | 1Y Target Price 69.73 | ||
Volume (30-day avg) 10 | Beta 2.33 | 52 Weeks Range 33.31 - 61.89 | Updated Date 08/30/2025 |
52 Weeks Range 33.31 - 61.89 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.73 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.58 | Actual -0.55 |
Profitability
Profit Margin 24.88% | Operating Margin (TTM) -758.04% |
Management Effectiveness
Return on Assets (TTM) 2.25% | Return on Equity (TTM) 8.61% |
Valuation
Trailing PE 80.89 | Forward PE 26.39 | Enterprise Value 3114392327 | Price to Sales(TTM) 17.56 |
Enterprise Value 3114392327 | Price to Sales(TTM) 17.56 | ||
Enterprise Value to Revenue 14.89 | Enterprise Value to EBITDA 116.04 | Shares Outstanding 62211300 | Shares Floating 43154747 |
Shares Outstanding 62211300 | Shares Floating 43154747 | ||
Percent Insiders 1.03 | Percent Institutions 116.26 |
Upturn AI SWOT
Protagonist Therapeutics Inc
Company Overview
History and Background
Protagonist Therapeutics Inc. was founded in 2006. It is a biopharmaceutical company with a focus on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Licensing: Engages in partnerships and licensing agreements to commercialize its products and technologies.
Leadership and Structure
Dinesh V. Patel, Ph.D., is the President and CEO. The company has a typical organizational structure with departments for research, development, clinical trials, and business operations. The board of directors provides governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Rusfertide (PTG-300): Rusfertide is an injectable hepcidin mimetic currently in Phase 3 development for the treatment of polycythemia vera (PV). As an investigational medicine, market share data is not applicable. Competitors include Jakafi (ruxolitinib) from Incyte and other treatments targeting PV symptoms.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on developing and commercializing new therapies for various diseases.
Positioning
Protagonist Therapeutics is positioned as a company specializing in peptide-based therapeutics, particularly in areas with unmet medical needs such as polycythemia vera.
Total Addressable Market (TAM)
The total addressable market for polycythemia vera and related indications is estimated to be substantial, potentially reaching billions of dollars annually. Protagonist is seeking to capture a significant portion of this market with Rusfertide, pending regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary peptide technology platform
- Focus on unmet medical needs
- Strong intellectual property portfolio
- Advancing clinical pipeline
Weaknesses
- Reliance on single lead product (Rusfertide)
- Clinical trial risks and regulatory hurdles
- Limited commercialization experience
- Cash Burn Rate
Opportunities
- Potential FDA approval and commercial launch of Rusfertide
- Expansion of pipeline with new peptide therapeutics
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory setbacks
- Patent expirations
Competitors and Market Share
Key Competitors
- INCY (Incyte)
- BMY (Bristol Myers Squibb)
- NVS (Novartis)
Competitive Landscape
Protagonist Therapeutics differentiates itself through its peptide-based drug discovery platform and focus on specific disease areas. Their main advantage will come from rusfertide approval and being a novel MOA.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to advancement in clinical trials and strategic partnerships.
Future Projections: Future growth is dependent on the successful development and commercialization of Rusfertide and other pipeline candidates. Analyst projections vary based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Focus on completing Phase 3 trials for Rusfertide and preparing for potential commercial launch.
Summary
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a promising lead product, Rusfertide, targeting polycythemia vera. Its success hinges on positive clinical trial results and regulatory approval. The company's reliance on a single lead product presents a risk, but potential partnerships and pipeline expansion offer opportunities for growth. They need to watch competitors and manage finances cautiously.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (10-K, 10-Q)
- Company website
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is estimated and may not be precise. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.protagonist-inc.com |
Full time employees 130 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.